Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
No sales in the U.S. -- yet.
No sales in Europe -- perhaps ever.
No new data on the pipeline.
Not exactly a good quarter for Arena Pharmaceuticals (NASDAQ: ARNA ) . Shares ended down more than 9% on Friday after reporting earnings Thursday night.
Most, and probably all, of that decline is because of the European decision, or lack thereof. Arena and its marketing partner, Eisai, decided to withdraw its application with the European Medicines Agency to market its obesity drug, Belviq. Withdrawing the application, rather than waiting for a rejection by the EMA, is a pretty common strategy that companies take in Europe.
http://www.fool.com/investing/general/2013/05/04/arena-pharmaceuticals-earnings-may-2nd.aspx
No sales in Europe -- perhaps ever.
No new data on the pipeline.
Not exactly a good quarter for Arena Pharmaceuticals (NASDAQ: ARNA ) . Shares ended down more than 9% on Friday after reporting earnings Thursday night.
Most, and probably all, of that decline is because of the European decision, or lack thereof. Arena and its marketing partner, Eisai, decided to withdraw its application with the European Medicines Agency to market its obesity drug, Belviq. Withdrawing the application, rather than waiting for a rejection by the EMA, is a pretty common strategy that companies take in Europe.
http://www.fool.com/investing/general/2013/05/04/arena-pharmaceuticals-earnings-may-2nd.aspx